CRISPR revolutionized biology, but its antiviral profile in humans is limited: we don't know how to efficiently deliver Cas9 into infected cells (no LNP/RNP delivery is viable open-source at broad clinical scale). That is why CRISPR sits in the Bactaegion cabinet as a canonical system (the pedagogical landmark) but not as a priority therapeutic target. The real drug leads are elsewhere — CBASS, Thoeris, RADAR. CRISPR is the mental bridge: once you understand how a bacterium memorizes and slices a virus, you understand why the other systems deserve a serious look.